Safety of recombinant and plasma-derived medicinals for the treatment of coagulopathies

New generations of recombinant and plasma-derived therapeutics, with improv ed purity and viral safety, are now available; however, these biotherapeuti cs may still carry risks of bloodborne or cell culture-derived virus transm ission, Creutzfeldt-Jakob disease or non-Creutzfeldt-Jakob disease transmis sion, and inhibitor development. Thus, ensuring their optimal safety profil e remains of critical importance, especially with regard to pathogen transm ission, thrombogenic risk, and immunogenicity.